Zealand Pharma

ZEAL.CO Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$298.00

+1.02% today

52W: $233.50 – $556.00

52W Low: $233.50 Position: 20% 52W High: $556.00

🔗 Compare Brokers

Key Metrics

P/E Ratio

3.3x

Price-to-Earnings

Forward P/E

57.23x

Forward Price/Earnings

P/S Ratio

2.28x

Price-to-Sales

EV/EBITDA

0.92x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$21B

Market Capitalization

Revenue Growth

661%

YoY Revenue Growth

Profit Margin

70.05%

Net profit margin

ROE

55.06%

Return on Equity

Beta

0.57

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

422,048

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

15 analysts

Avg. Price Target

$538.07

+80.56% upside

Target Range

$275.00 – $825.00

About the Company

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is

Sector: Healthcare Industry: Biotechnology Country: Denmark Employees: 481 Exchange: CPH